<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03109873</url>
  </required_header>
  <id_info>
    <org_study_id>16D.639</org_study_id>
    <nct_id>NCT03109873</nct_id>
  </id_info>
  <brief_title>Metformin Hydrochloride in Affecting Cytokines and Exosomes in Patients With Head and Neck Cancer</brief_title>
  <official_title>Pilot Study of Metformin in Head and Neck Cancer and Its Effect on Proinflammatory Cytokines and Exosomes Implicated in Acute and Chronic Toxicity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sidney Kimmel Cancer Center at Thomas Jefferson University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Thomas Jefferson University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This pilot clinical trial studies how well metformin hydrochloride works in affecting
      cytokines and exosomes in patients with head and neck cancer. Metformin hydrochloride may
      reduce the metabolic activity of cancer cells and of surrounding supportive tissues.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To assess the capacity of metformin hydrochloride (metformin) to alter the cytokine and
      exosome profiles.

      II. To assess the capacity of metformin to mitigate known side effects of external beam
      radiation therapy including inflammation, mucositis, dysphagia, xerostomia, and fatigue.

      SECONDARY OBJECTIVES:

      I. Assess safety and tolerability of metformin treatment in subjects undergoing external beam
      radiation treatment for head and neck cancer.

      II. To determine the effect of metformin treatment on symptoms of xerostomia as assessed by
      the Xerostomia Questionnaire (XQ).

      III. To determine the effect of metformin treatment on symptoms of mucositis as assessed by
      World Health Organization (WHO) classification.

      IV. To determine the effect of metformin treatment on symptoms of dysphagia as assessed by
      the MD Anderson Dysphagia Inventory.

      V. To determine the effect of metformin treatment on symptoms of fatigue as assess by the
      Multidimensional Fatigue Inventory (MFI).
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 5, 2017</start_date>
  <completion_date type="Anticipated">June 2020</completion_date>
  <primary_completion_date type="Actual">April 4, 2018</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cytokine/Chemokine Profile</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Mixed effects linear regression will be used to model longitudinal measurements of each cytokine.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mucositis Assessed Using WHO Classification</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Analysis will be primarily descriptive. The distribution of swallowing function and mucositis scores will be summarized by arm using means, medians, standard deviations, and ranges.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>The objective response rate will be estimated by arm along with an exact 95% binomial confidence interval</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Exosome Profile</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Longitudinal measurements of exosomes will also be modeled using mixed effects linear regression. This analysis is treated as separate from the cytokine questions and the p-value will not be adjusted.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Toxicities</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Evaluated according to National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">9</enrollment>
  <condition>Larynx</condition>
  <condition>Lip</condition>
  <condition>Oral Cavity</condition>
  <condition>Pharynx</condition>
  <arm_group>
    <arm_group_label>Arm I (EBRT, metformin hydrochloride)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients undergo External Beam Radiation Therapy (EBRT). Beginning 1 week prior to start of EBRT, patients receive metformin hydrochloride PO QD for 3 days and BID thereafter until 2 weeks after completion of EBRT.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II (EBRT, placebo)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients undergo External Beam Radiation Therapy (EBRT). Beginning 1 week prior to start of EBRT, patients receive placebo PO QD for 3 days and BID thereafter until 2 weeks after completion of EBRT.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>External Beam Radiation Therapy</intervention_name>
    <description>Undergo External Beam Radiation Therapy</description>
    <arm_group_label>Arm I (EBRT, metformin hydrochloride)</arm_group_label>
    <arm_group_label>Arm II (EBRT, placebo)</arm_group_label>
    <other_name>Definitive Radiation Therapy</other_name>
    <other_name>EBRT</other_name>
    <other_name>External Beam RT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin Hydrochloride</intervention_name>
    <description>Given orally</description>
    <arm_group_label>Arm I (EBRT, metformin hydrochloride)</arm_group_label>
    <other_name>1,1-Dimethylbiguanide Hydrochloride</other_name>
    <other_name>1115-70-4</other_name>
    <other_name>91485</other_name>
    <other_name>Cidophage</other_name>
    <other_name>Glucoformin</other_name>
    <other_name>Glucophage ER</other_name>
    <other_name>Dimefor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Given orally</description>
    <arm_group_label>Arm II (EBRT, placebo)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects with a diagnosis of head and neck cancer biopsy proven, and who are
             candidates for radiation therapy

          -  All subjects must be able to comprehend and sign a written informed consent document.

        Exclusion Criteria:

          -  Subjects who are pregnant or may become pregnant during metformin administration;
             pregnancy testing will be done in conjunction with preradiation protocols

          -  Subjects on metformin for any reason during the preceding 4 weeks

          -  Diabetic subjects are eligible if they are not taking metformin or insulin

          -  Subjects who have received iodinated contrast dye must wait 12 hours prior to starting
             Metformin. If a CT scan with contrast is scheduled after screening and consent, the
             metformin cannot be taken until after the CT with contrast has been completed and they
             have waited 12 hours.

          -  Patients with plasma creatinine level greater than 1.3 mg/dL

          -  Patients with plasma bicarbonate less than 22 mEq/L or history of lactic or any other
             metabolic acidosis

          -  Patients with history of congestive heart failure

          -  Patients with myocardial ischemia or peripheral muscle ischemia

          -  Patients with sepsis or severe infection

          -  Patients with history of lung disease currently requiring any supplemental oxygen
             treatment

          -  Patients scheduled for radiation less than 6 days from enrollment

          -  Patients with history of hepatic dysfunction or hepatic disease and abnormal liver
             function tests; patients who have a history of hepatic dysfunction or hepatic disease
             and normal liver function tests will be eligible to participate

          -  Patients with a current history (in the past 30 days) of heaving drinking which is
             defined in accordance with CDC definition as more than 8 drinks per week for women and
             more than 15 drinks per week for men. A standard drink contains .6 ounces of pure
             alcohol. Generally, this amount of pure alcohol is found in 12-ounces of beer,
             8-ounces of malt liquor, 5-ounces of wine, 1.5-ounces or a &quot;shot&quot; of 80-proof
             distilled spirits or liquor (e.g., gin, rum, vodka, or whiskey). While on study,
             patients should limit their alcohol consumption to no more than 8 drinks per week for
             women and no more than 15 drinks per week for men. Patients who feel they cannot
             comply with this recommendation are not eligible&quot;.

          -  All medications are permitted except those that are contraindicated with metformin
             under current Food and Drug Administration (FDA) recommendations
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Adam Luginbuhl, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sidney Kimmel Cancer Center at Thomas Jefferson University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sidney Kimmel Cancer Center at Thomas Jefferson University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.kimmelcancercenter.org</url>
    <description>Sidney Kimmel Cancer Center</description>
  </link>
  <link>
    <url>http://hospitals.jefferson.edu/</url>
    <description>Thomas Jefferson University Hospital</description>
  </link>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>March 6, 2017</study_first_submitted>
  <study_first_submitted_qc>April 5, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 12, 2017</study_first_posted>
  <results_first_submitted>October 29, 2019</results_first_submitted>
  <results_first_submitted_qc>October 29, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">November 20, 2019</results_first_posted>
  <last_update_submitted>December 13, 2019</last_update_submitted>
  <last_update_submitted_qc>December 13, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 16, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Head and Neck Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 20, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/73/NCT03109873/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Arm I (EBRT, Metformin Hydrochloride)</title>
          <description>Patients undergo External Beam Radiation Therapy (EBRT). Beginning 1 week prior to start of EBRT, patients receive metformin hydrochloride PO QD for 3 days and BID thereafter until 2 weeks after completion of EBRT.
External Beam Radiation Therapy: Undergo External Beam Radiation Therapy
Metformin Hydrochloride: Given orally</description>
        </group>
        <group group_id="P2">
          <title>Arm II (EBRT, Placebo)</title>
          <description>Patients undergo External Beam Radiation Therapy (EBRT). Beginning 1 week prior to start of EBRT, patients receive placebo PO QD for 3 days and BID thereafter until 2 weeks after completion of EBRT.
External Beam Radiation Therapy: Undergo External Beam Radiation Therapy
Placebo: Given orally</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Arm I (EBRT, Metformin Hydrochloride)</title>
          <description>Patients undergo External Beam Radiation Therapy (EBRT). Beginning 1 week prior to start of EBRT, patients receive metformin hydrochloride PO QD for 3 days and BID thereafter until 2 weeks after completion of EBRT.
External Beam Radiation Therapy: Undergo External Beam Radiation Therapy
Metformin Hydrochloride: Given orally</description>
        </group>
        <group group_id="B2">
          <title>Arm II (EBRT, Placebo)</title>
          <description>Patients undergo External Beam Radiation Therapy (EBRT). Beginning 1 week prior to start of EBRT, patients receive placebo PO QD for 3 days and BID thereafter until 2 weeks after completion of EBRT.
External Beam Radiation Therapy: Undergo External Beam Radiation Therapy
Placebo: Given orally</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="5"/>
            <count group_id="B2" value="4"/>
            <count group_id="B3" value="9"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Cytokine/Chemokine Profile</title>
        <description>Mixed effects linear regression will be used to model longitudinal measurements of each cytokine.</description>
        <time_frame>Up to 1 year</time_frame>
        <population>Due to insufficient accrual, statistical results cannot be reported.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm I (EBRT, Metformin Hydrochloride)</title>
            <description>Patients undergo External Beam Radiation Therapy (EBRT). Beginning 1 week prior to start of EBRT, patients receive metformin hydrochloride PO QD for 3 days and BID thereafter until 2 weeks after completion of EBRT.
External Beam Radiation Therapy: Undergo External Beam Radiation Therapy
Metformin Hydrochloride: Given orally</description>
          </group>
          <group group_id="O2">
            <title>Arm II (EBRT, Placebo)</title>
            <description>Patients undergo External Beam Radiation Therapy (EBRT). Beginning 1 week prior to start of EBRT, patients receive placebo PO QD for 3 days and BID thereafter until 2 weeks after completion of EBRT.
External Beam Radiation Therapy: Undergo External Beam Radiation Therapy
Placebo: Given orally</description>
          </group>
        </group_list>
        <measure>
          <title>Cytokine/Chemokine Profile</title>
          <description>Mixed effects linear regression will be used to model longitudinal measurements of each cytokine.</description>
          <population>Due to insufficient accrual, statistical results cannot be reported.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mucositis Assessed Using WHO Classification</title>
        <description>Analysis will be primarily descriptive. The distribution of swallowing function and mucositis scores will be summarized by arm using means, medians, standard deviations, and ranges.</description>
        <time_frame>Up to 1 year</time_frame>
        <population>Due to insufficient accrual, statistical results cannot be reported.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm I (EBRT, Metformin Hydrochloride)</title>
            <description>Patients undergo External Beam Radiation Therapy (EBRT). Beginning 1 week prior to start of EBRT, patients receive metformin hydrochloride PO QD for 3 days and BID thereafter until 2 weeks after completion of EBRT.
External Beam Radiation Therapy: Undergo External Beam Radiation Therapy
Metformin Hydrochloride: Given orally</description>
          </group>
          <group group_id="O2">
            <title>Arm II (EBRT, Placebo)</title>
            <description>Patients undergo External Beam Radiation Therapy (EBRT). Beginning 1 week prior to start of EBRT, patients receive placebo PO QD for 3 days and BID thereafter until 2 weeks after completion of EBRT.
External Beam Radiation Therapy: Undergo External Beam Radiation Therapy
Placebo: Given orally</description>
          </group>
        </group_list>
        <measure>
          <title>Mucositis Assessed Using WHO Classification</title>
          <description>Analysis will be primarily descriptive. The distribution of swallowing function and mucositis scores will be summarized by arm using means, medians, standard deviations, and ranges.</description>
          <population>Due to insufficient accrual, statistical results cannot be reported.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Objective Response Rate</title>
        <description>The objective response rate will be estimated by arm along with an exact 95% binomial confidence interval</description>
        <time_frame>Up to 2 years</time_frame>
        <population>Due to insufficient accrual, statistical results cannot be reported.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm I (EBRT, Metformin Hydrochloride)</title>
            <description>Patients undergo External Beam Radiation Therapy (EBRT). Beginning 1 week prior to start of EBRT, patients receive metformin hydrochloride PO QD for 3 days and BID thereafter until 2 weeks after completion of EBRT.
External Beam Radiation Therapy: Undergo External Beam Radiation Therapy
Metformin Hydrochloride: Given orally</description>
          </group>
          <group group_id="O2">
            <title>Arm II (EBRT, Placebo)</title>
            <description>Patients undergo External Beam Radiation Therapy (EBRT). Beginning 1 week prior to start of EBRT, patients receive placebo PO QD for 3 days and BID thereafter until 2 weeks after completion of EBRT.
External Beam Radiation Therapy: Undergo External Beam Radiation Therapy
Placebo: Given orally</description>
          </group>
        </group_list>
        <measure>
          <title>Objective Response Rate</title>
          <description>The objective response rate will be estimated by arm along with an exact 95% binomial confidence interval</description>
          <population>Due to insufficient accrual, statistical results cannot be reported.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Exosome Profile</title>
        <description>Longitudinal measurements of exosomes will also be modeled using mixed effects linear regression. This analysis is treated as separate from the cytokine questions and the p-value will not be adjusted.</description>
        <time_frame>Up to 1 year</time_frame>
        <population>Due to insufficient accrual, statistical results cannot be reported.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm I (EBRT, Metformin Hydrochloride)</title>
            <description>Patients undergo External Beam Radiation Therapy (EBRT). Beginning 1 week prior to start of EBRT, patients receive metformin hydrochloride PO QD for 3 days and BID thereafter until 2 weeks after completion of EBRT.
External Beam Radiation Therapy: Undergo External Beam Radiation Therapy
Metformin Hydrochloride: Given orally</description>
          </group>
          <group group_id="O2">
            <title>Arm II (EBRT, Placebo)</title>
            <description>Patients undergo External Beam Radiation Therapy (EBRT). Beginning 1 week prior to start of EBRT, patients receive placebo PO QD for 3 days and BID thereafter until 2 weeks after completion of EBRT.
External Beam Radiation Therapy: Undergo External Beam Radiation Therapy
Placebo: Given orally</description>
          </group>
        </group_list>
        <measure>
          <title>Exosome Profile</title>
          <description>Longitudinal measurements of exosomes will also be modeled using mixed effects linear regression. This analysis is treated as separate from the cytokine questions and the p-value will not be adjusted.</description>
          <population>Due to insufficient accrual, statistical results cannot be reported.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Toxicities</title>
        <description>Evaluated according to National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0</description>
        <time_frame>Up to 2 years</time_frame>
        <population>Due to insufficient accrual, statistical results cannot be reported.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm I (EBRT, Metformin Hydrochloride)</title>
            <description>Patients undergo External Beam Radiation Therapy (EBRT). Beginning 1 week prior to start of EBRT, patients receive metformin hydrochloride PO QD for 3 days and BID thereafter until 2 weeks after completion of EBRT.
External Beam Radiation Therapy: Undergo External Beam Radiation Therapy
Metformin Hydrochloride: Given orally</description>
          </group>
          <group group_id="O2">
            <title>Arm II (EBRT, Placebo)</title>
            <description>Patients undergo External Beam Radiation Therapy (EBRT). Beginning 1 week prior to start of EBRT, patients receive placebo PO QD for 3 days and BID thereafter until 2 weeks after completion of EBRT.
External Beam Radiation Therapy: Undergo External Beam Radiation Therapy
Placebo: Given orally</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Toxicities</title>
          <description>Evaluated according to National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0</description>
          <population>Due to insufficient accrual, statistical results cannot be reported.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>baseline through one year after completion of treatment</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Arm I (EBRT, Metformin Hydrochloride)</title>
          <description>Patients undergo External Beam Radiation Therapy (EBRT). Beginning 1 week prior to start of EBRT, patients receive metformin hydrochloride PO QD for 3 days and BID thereafter until 2 weeks after completion of EBRT.
External Beam Radiation Therapy: Undergo External Beam Radiation Therapy
Metformin Hydrochloride: Given orally</description>
        </group>
        <group group_id="E2">
          <title>Arm II (EBRT, Placebo)</title>
          <description>Patients undergo External Beam Radiation Therapy (EBRT). Beginning 1 week prior to start of EBRT, patients receive placebo PO QD for 3 days and BID thereafter until 2 weeks after completion of EBRT.
External Beam Radiation Therapy: Undergo External Beam Radiation Therapy
Placebo: Given orally</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Xerostomia</sub_title>
                <description>Dry mouth</description>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Adam Luginbuhl</name_or_title>
      <organization>Sidney Kimmel Cancer Center at Thomas Jefferson University</organization>
      <phone>215-240-0748</phone>
      <email>adam.luginbuhl@jefferson.ed</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

